$FSK

Schall Law Firm seeks $FSK investors for class action lawsuit alleging false statements on portfolio restructuring, valuations, and dividend strength between May 2024 and February 2026.

Class action alleges FS KKR Capital misrepresented portfolio restructuring, valuations, and distribution sustainability from May 2024 through February 2026.

Rosen Law Firm files class action against FS KKR Capital Corp. ($FSK) alleging misstatements on portfolio valuations and distribution sustainability. Lead plaintiff deadline: July 3, 2026.

Four companies face securities fraud investigations alleging executive misstatements about valuations, acquisitions, and revenue prospects. Eligible shareholders may seek compensation at no upfront cost.

Schall Law Firm seeks investors in $FSK securities fraud class action, alleging false statements on portfolio restructuring, valuation, and dividends.

Class action lawsuit filed against $FSK alleging false statements on portfolio restructuring, valuations, and distribution strategy from May 2024 to February 2026.

Securities lawsuit filed against $FSK alleging overstated portfolio valuations and distribution sustainability. Stock fell 8.2% to $18.58 after Q2 NAV dropped 6.2% to $21.93.

Class action lawsuit alleges FS KKR Capital made false statements about portfolio valuations, restructuring, and dividend sustainability amid significant NAV declines and rising non-accruals.

Diameter Capital initiates $33.65M position in $FSK as shares plunge 51% to $9.99, offering 25% dividend yield despite credit risks.

FSK stock crashed 19% on dividend cut to $0.48/share and disclosure of $440M non-accrual portfolio assets, prompting securities fraud investigation.

Pomerantz LLP investigates potential investor claims against Aardvark Therapeutics and FS KKR Capital Corp, while retracting prior Ambarella notice.

Pomerantz Law Firm investigates $FSK over potential securities fraud following steep dividend cut and $440M non-accrual investment disclosure.